UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.
ORIGINAL SOURCE →via Biopharma Dive
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · CN
- [HEALTH] Who writes the pandemic? State power, individual subjectivity, and the history of the present in China's COVID-19 respon
- [ENERGY] Power of Siberia 2 creates strategic risk-hedging mechanism for China — expert
- [ENERGY] Is China less exposed than its neighbors to oil crises? | DW News
- [CONFLICT] China invokes anti-sanctions law to counter US blacklisting of refiners - Reuters
- [TECH] Nvidia açıkladı: Çin'de pazar payı sıfıra düştü
- [FINANCE] US sanctions China-based crude oil terminal operator for trading Iran oil